Yayın:
Effect of ketoprofen co‐administration on pharmacokinetics of cefquinome following repeated administration in goats

dc.contributor.authorTekeli, Ibrahim Ozan
dc.contributor.authorTurk, Erdinc
dc.contributor.authorDurna Corum, Duygu
dc.contributor.authorCorum, Orhan
dc.contributor.authorKirgiz, Fatma Ceren
dc.contributor.authorSakin, Fatih
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-01-04T14:28:49Z
dc.date.issued2020-08-19
dc.description.abstractThe pharmacokinetics of cefquinome (2 mg/kg every 24 hr for 5 days) was determined following intramuscular administration alone and co‐administration with ketoprofen (3 mg/kg every 24 hr for 5 days) in goats. Six goats were used for the study. In the study, the crossover pharmacokinetics design with 20‐day washout period was performed in two periods. Plasma concentrations of cefquinome were assayed using high‐performance liquid chromatography by ultraviolet detection. The mean terminal elimination half‐life (t1/2ʎz), area under the concentration–time curve (AUC0–24), peak concentration (Cmax), apparent volume of distribution (Vdarea/F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose. Ketoprofen significantly prolonged t1/2ʎz of cefquinome, increased AUC0–24 and Cmax, and decreased Vdarea/F and CL/F. Cefquinome exhibited low accumulation after the administration alone and in combination with ketoprofen. These results indicated that ketoprofen prolonged the elimination of cefquinome in goats. The 24‐hr dosing intervals at 2 mg/kg dose of cefquinome, which co‐administered with ketoprofen, may maintain T> minimum inhibitory concentration (MIC) values above 40% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 μg/ml in goats with an inflammatory condition.
dc.description.urihttps://doi.org/10.1111/jvp.12904
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/32815194
dc.description.urihttps://dx.doi.org/10.1111/jvp.12904
dc.identifier.doi10.1111/jvp.12904
dc.identifier.eissn1365-2885
dc.identifier.endpage447
dc.identifier.issn0140-7783
dc.identifier.openairedoi_dedup___::9a22e43e709a5ffd953dd7400a926cf4
dc.identifier.orcid0000-0002-6845-2279
dc.identifier.orcid0000-0003-1735-1774
dc.identifier.orcid0000-0003-1567-991x
dc.identifier.orcid0000-0003-3168-2510
dc.identifier.orcid0000-0002-8454-5336
dc.identifier.orcid0000-0001-5377-0322
dc.identifier.orcid0000-0002-8674-4873
dc.identifier.pubmed32815194
dc.identifier.scopus2-s2.0-85089693109
dc.identifier.startpage440
dc.identifier.urihttps://hdl.handle.net/20.500.12597/38204
dc.identifier.volume43
dc.identifier.wos000560601300001
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.rightsCLOSED
dc.subjectMale
dc.subjectCross-Over Studies
dc.subjectGoats
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectInjections, Intramuscular
dc.subjectDrug Administration Schedule
dc.subjectAnti-Bacterial Agents
dc.subjectCephalosporins
dc.subjectKetoprofen
dc.subjectArea Under Curve
dc.subjectAnimals
dc.subjectDrug Interactions
dc.subjectHalf-Life
dc.subject.sdg3. Good health
dc.titleEffect of ketoprofen co‐administration on pharmacokinetics of cefquinome following repeated administration in goats
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Ibrahim Ozan Tekeli","name":"Ibrahim Ozan","surname":"Tekeli","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-6845-2279"},"provenance":null}},{"fullName":"Erdinc Turk","name":"Erdinc","surname":"Turk","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1735-1774"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Fatma Ceren Kirgiz","name":"Fatma Ceren","surname":"Kirgiz","rank":5,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8454-5336"},"provenance":null}},{"fullName":"Fatih Sakin","name":"Fatih","surname":"Sakin","rank":6,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0001-5377-0322"},"provenance":null}},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":7,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Male"},"provenance":null},{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cross-Over Studies"},"provenance":null},{"subject":{"scheme":"keyword","value":"Goats"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Inflammatory Agents, Non-Steroidal"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intramuscular"},"provenance":null},{"subject":{"scheme":"keyword","value":"Drug Administration Schedule"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Bacterial Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cephalosporins"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Ketoprofen"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Drug Interactions"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Effect of ketoprofen co‐administration on pharmacokinetics of cefquinome following repeated administration in goats","subTitle":null,"descriptions":["<jats:p>The pharmacokinetics of cefquinome (2 mg/kg every 24 hr for 5 days) was determined following intramuscular administration alone and co‐administration with ketoprofen (3 mg/kg every 24 hr for 5 days) in goats. Six goats were used for the study. In the study, the crossover pharmacokinetics design with 20‐day washout period was performed in two periods. Plasma concentrations of cefquinome were assayed using high‐performance liquid chromatography by ultraviolet detection. The mean terminal elimination half‐life (t<jats:sub>1/2ʎz</jats:sub>), area under the concentration–time curve (AUC<jats:sub>0–24</jats:sub>), peak concentration (C<jats:sub>max</jats:sub>), apparent volume of distribution (V<jats:sub>darea</jats:sub>/F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose. Ketoprofen significantly prolonged t<jats:sub>1/2ʎz</jats:sub> of cefquinome, increased AUC<jats:sub>0–24</jats:sub> and C<jats:sub>max</jats:sub>, and decreased V<jats:sub>darea</jats:sub>/F and CL/F. Cefquinome exhibited low accumulation after the administration alone and in combination with ketoprofen. These results indicated that ketoprofen prolonged the elimination of cefquinome in goats. The 24‐hr dosing intervals at 2 mg/kg dose of cefquinome, which co‐administered with ketoprofen, may maintain T&gt; minimum inhibitory concentration (MIC) values above 40% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 μg/ml in goats with an inflammatory condition.</jats:p>"],"publicationDate":"2020-08-19","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_14cb","label":"CLOSED","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"447","iss":null,"sp":"440","vol":"43","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::9a22e43e709a5ffd953dd7400a926cf4","originalIds":["10.1111/jvp.12904","50|doiboost____|9a22e43e709a5ffd953dd7400a926cf4","32815194","3081062822"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12904"},{"scheme":"pmid","value":"32815194"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":6,"influence":2.7005849e-9,"popularity":6.0486838e-9,"impulse":4,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12904"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12904"],"publicationDate":"2020-08-19","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"32815194"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12904"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/32815194"],"publicationDate":"2021-06-02","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12904"},{"scheme":"mag_id","value":"3081062822"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12904"],"refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar